MOR 107

Drug Profile

MOR 107

Alternative Names: lanthionine-peptides; lantipeptides; LP 2

Latest Information Update: 16 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lanthio Pharma; MorphoSys
  • Class Antifibrotics; Peptides
  • Mechanism of Action G protein-coupled receptor modulators; Intracellular signalling peptide and protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diabetic nephropathies; Fibrosis

Most Recent Events

  • 01 Feb 2017 Phase-I clinical trials in Diabetic nephropathies (In volunteers) in United Kingdom (SC) (NCT03067363)
  • 01 Feb 2017 Phase-I clinical trials in Fibrosis (In volunteers) in United Kingdom (SC) (NCT03067363)
  • 19 Sep 2016 Preclinical development is ongoing Netherlands and Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top